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Abstract
Purpose
The aim of this study was to investigate the prognostic performance of multiparametric mag-
netic resonance imaging (mpMRI) and Prostate Imaging Reporting and Data System (PIR-
ADS) score in predicting pathologic features in a cohort of patients eligible for active
surveillance who underwent radical prostatectomy.
Methods
A total of 223 patients who fulfilled the criteria for “Prostate Cancer Research International:
Active Surveillance”, were included. Mp–1.5 Tesla MRI examination staging with endorectal
coil was performed at least 6–8 weeks after TRUS-guided biopsy. In all patients, the
likelihood of the presence of cancer was assigned using PIRADS score between 1 and 5.
Outcomes of interest were: Gleason score upgrading, extra capsular extension (ECE),
unfavorable prognosis (occurrence of both upgrading and ECE), large tumor volume
(0.5ml), and seminal vesicle invasion (SVI). Receiver Operating Characteristic (ROC)
curves and Decision Curve Analyses (DCA) were performed for models with and without
inclusion of PIRADS score.
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Results
Multivariate analysis demonstrated the association of PIRADS score with upgrading
(P<0.0001), ECE (P<0.0001), unfavorable prognosis (P<0.0001), and large tumor volume
(P = 0.002). ROC curves and DCA showed that models including PIRADS score resulted in
greater net benefit for almost all the outcomes of interest, with the only exception of SVI.
Conclusions
mpMRI and PIRADS scoring are feasible tools in clinical setting and could be used as deci-
sion-support systems for a more accurate selection of patients eligible for AS.
Introduction
The use of prostate specific antigen (PSA) testing has recently been criticized for prostate can-
cer (PCa) screening[1,2], although it continues to be the best biomarker available for early PCa
detection. The increasing use of this biomarker in association with several PSA derivatives,
such as free to total PSA ratio (%fPSA), PSA density (PSAD), and PSA velocity, has led to fre-
quent detection of small, well differentiated, low-risk PCa without significant decrease in mor-
tality[3]. This fact gives rise to the thought that clinically insignificant disease is being treated
excessively and active follow up of these patients should be preferred instead of radical treat-
ment. Active surveillance (AS) is an alternative to initial radical treatment of low-risk PCa,
even if the current parameters used for selection and follow up, such as clinical T stage, total
PSA, PSA density, Gleason score (GS), and number of positive prostate biopsy cores, incor-
rectly exclude some patients eligible for AS and misclassify some who actually harbor signifi-
cant disease[4]. In order to predict the pathologic findings at radical prostatectomy, risk
stratification has been improved with validation of several nomograms that aid to reduce the
rates of overtreatment in patients with clinically insignificant PCa[5]. Consequently numerous
preoperative prognostic tools have analyzed the ability of prostate cancer antigen 3 (PCA3),
sarcosine, [–2]proPSA, and Prostate Health Index (PHI) in predicting pathological features at
radical prostatectomy[6,7]. Multiparametric magnetic resonance imaging (mpMRI) is increas-
ingly being used in clinical practice to evaluate PCa localization, tumor stage and aggres-
siveness aiding treatment planning[8]. Although many studies available on the role of mpMRI
during PCa-AS have shown the ability to reduce re-biopsies[9,10], not always MRI lesions cor-
respond with guided biopsy or radical prostatectomy (RP) specimen findings[11]. Recently
preoperative neural network software including mpMRI variables, PSA level and GS has been
reported to predict insignificant prostate cancer, particularly in the context of clinically non-
palpable tumors, suggesting a prognostic and pathologic predictive role in clinically very low
risk PCa[12]. In this scenario it has been developed a scoring system called Prostate Imaging
Reporting and Data System (PIRADS), with the aim to enable elaboration, interpretation, and
reporting of prostate mpMRI findings[13]. The aim of this study is to investigate the prognostic
performance of MRI and PIRADS score in predicting pathologic features in a cohort of patients
eligible for active surveillance who underwent RP.
Patients and Methods
We retrospectively reviewed the medical records of 2,200 patients who underwent robotic RP
for PCa between November 2009 and July 2014. None of the patients included in the current
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study received neoadjuvant androgen-deprivation therapy or drugs that could alter the PSA
values. In total 223 patients fulfilled the inclusion criteria for “Prostate Cancer Research Inter-
national: Active Surveillance”[14] defined as follows: clinical stage T2a or less, PSA<10 ng/ml,
2 or fewer cores involved with cancer after a 12-core biopsy scheme, GS6 grade and PSA den-
sity<0.2ng/mL/cc. We compared the pathological findings between prostate biopsies and spec-
imens after RP. Specimens were processed and evaluated according to the Stanford protocol
[15] by a single, experienced, genitourinary pathologist(G.R.) blinded to index-tests results.
After fixing the RP specimens, they were inked and cut at 3-mm intervals perpendicular to the
rectal surface. The apical slice was cut para-sagittally at 2-3-mm intervals, and the sections
were then divided in halves or quadrants to fit routinely used cassettes for paraffin embedding.
The whole prostate was sampled.
This retrospective analysis of prospectively acquired data was approved by the “IRCCS—
Istituto Europeo di Oncologia Ethic Committee” who waived the requirement for informed
consent specific to the study because all patients provided written informed consent for MR
imaging, surgical procedures, and research use of their medical information.
Mp–1.5 Tesla MRI (Avanto; Siemens Medical Solutions, Erlangen, Germany), examination
staging with endorectal coil was performed at least 6–8 weeks after TRUS-guided biopsy, in
order to avoid distortions and artifacts due to inflammatory process after the bioptic proce-
dure. The following pulse sequences were used: sagittal, coronal, and axial T2-TSE (TR/TE,
831/80 ms), axial Diffusion-Weighted Imaging (DWI) using high b values (b = 800) and ADC
maps, axial Dynamic Contrast-Enhanced imaging (DCE) obtained before, during and after
injection of gadopentetate dimeglumine (Magnevist; Bayer Healthcare, Berlin, Germany)
administered at a dose of 0.1 mmol per kilogram of body weight through a peripheral vein at a
flow rate of 3 mL/sec followed by a saline bolus of 10 mL administered at the same flow rate by
using a mechanical injector (Spectris MR Injection System; Medrad, Leverkusen, Germany)
and axial T1-TSE (TR/TE, 217.8/4.6).
The European Society of Urogenital Radiology (ESUR) in 2012 established clinical guide-
lines for the acquisition, interpretation, and reporting of mpMRI of the prostate in order to
facilitate a greater level of standardisation and consistency[16]. These recommendations, popu-
larly referred to as Prostate Imaging Reporting and Data System (PI-RADS), were based on lit-
erature evidence and consensus expert opinion.
One radiologist (G.P.) prospectively read and scored all cases, developing a standardized
structured report for each patient. In all patients, the likelihood of the presence of cancer was
assigned using PIRADS score (Likert-like scale) between 1 and 5 (1, not suspect; 2, hardly sus-
pect; 3, ambiguous; 4, suspect; 5, highly suspect)[17]. The assigned scores of 3–5 were consid-
ered positive, and scores of 1–2 were considered negative for cancer. For patients with more
than one region suspected to be cancer, only the region with the highest sum of the PIRADS
scores was used for statistical analysis.
Statistical Analysis
Outcomes of interest were: upgrading, extracapsular extension (ECE), unfavorable prognosis
(occurrence of both upgrading and ECE), large tumor volume (0.5ml) seminal vesicle inva-
sion (SVI). Unfavorable prognosis was also evaluated considering separately unfavorable prog-
nosis with primary GS = 4. Informative parameters for the distribution of continuous variables
(age, PSA, PSAD, prostate volume) were calculated and their distributions were tested for nor-
mality by the Kolmogorov-Smirnov test. Univariate analyses were performed to evaluate the
association of patient and tumor characteristics with upgrading, ECE, unfavorable prognosis,
large tumor volume and seminal vesicle invasion. The association for continuous variables was
Prostate Cancer Prognosis and Magnetic Resonance Imaging
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assessed by T-test or non-parametric two-sample Wilcoxon test, as appropriate; the association
for categorical variables was assessed by Chi-Square test or Fisher’s Exact Test, as appropriate.
Sensitivity, specificity, positive predicted values (PPV) and negative predicted values (NPV) for
PIRADS score 3–5 (positive for cancer) versus 1–2 (negative for cancer) were calculated for
each outcome of interest. Multivariate unconditional logistic regression models were per-
formed to assess the independent contribution of patient and tumor characteristics in the pre-
diction of upgrading, ECE, unfavorable prognosis, large tumor volume and seminal vesicle
Table 1. Patient and tumor characteristics of the study population.
N (%)
Volume^ 47.94 (±14.53)
Age^ 62.75 (±8.28)
Clinical Stage
cT1c 191 (85.65%)
cT2a 32 (14.35%)
PSA^ 6.02 (±1.91)
PSA Density^ 0.13 (±0.04)
Tumor volume^ 0.95 (±0.23)
Pathological stage
pT2a 23 (10.31%)
pT2b 3 (1.35%)
pT2c 145 (65.02%)
pT3a 45 (20.18%)
pT3b 7 (3.14%)
Positive Cores
1 95 (42.60%)
2 128 (57.40%)
Pathological Total Gleason Score
6 110 (49.33%)
7 110 (49.33%)
8 2 (0.90%)
9 1 (0.45%)
Cancer at MRI
Not visible 19 (8.52%)
Visible 204 (91.48%)
Positive lymph nodes
Yes 4 (1.79%)
No 219 (98.21%)
Seminal vesicle invasion
Yes 7 (3.15%)
No 215 (96.85%)
PIRADS
1 2 (0.91%)
2 14 (6.36%)
3 58 (26.36%)
4 71 (32.27%)
5 75 (34.09%)
^mean (± SD)
doi:10.1371/journal.pone.0139696.t001
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invasion; Odds Ratios (OR) and 95% Confidence Intervals (CI) were calculated. Receiver Oper-
ating Characteristic (ROC) curves were drawn for models with and without inclusion of PIR-
ADS score, and the corresponding areas under the curve (AUC) of the two models were
compared with the De Long test. To graphically evaluate the net benefit for the models with
and without inclusion of PIRADS score, a decision-curve analysis (DCA) was performed. DCA
expresses the ‘‘net benefit” of a prediction model as the difference between the proportion of
Table 2. Sensitivity (SE), specificity (SP), positive predicted values (PPV) and negative predicted val-
ues (NPV) with 95%(CI) for 1–2 vs. 3 PIRADS score.
SE(CI)* SP(CI)* PPV(CI)* NPV(CI)*
Upgrading 99 (95–100) 14 (8–22) 55 (48–62) 94 (70–100)
Extra capsular extension 100 (93–100) 10 (6–15) 25 (20–32) 100 (79–100)
Unfavorable prognosis 100 (91–100) 9 (5–14) 19 (14–25) 100 (79–100)
Tumor volume 94 (90–97) 40 (12–74) 97 (94–99) 25 (7–52)
Seminal vesicle invasion 100 (59–100) 8 (4–12) 3 (1–7) 100 (79–100)
*Percentage
doi:10.1371/journal.pone.0139696.t002
Table 3. Association of patient and tumor characteristics withupgrading: univariate andmultivariate analysis.
Upgrading Pvalue* Multivariate Odds Ratio (95%CI) Pvalue
“Yes” N (%) “No” N (%)
Volume^ 47.55 (±10.25) 48.34 (±17.94) 0.43 1.00 (0.98–1.03)2 0.92
Age^ 63.35 (±9.38) 62.13 (±6.96) 0.04 1.01 (0.98–1.05)2 0.53
Clinical Stage 0.34 0.59
cT1c 94 (83%) 97 (88%) 1.00 (reference)
cT2a 19 (17%) 13 (12%) 1.27 (0.54–2.97)
PSA^ 6.09 (±1.95) 5.94 (±1.87) 0.56 1.02 (0.86–1.19)2 0.85
PSA Density^ 0.13 (±0.04) 0.13 (±0.04) 0.76 -3 -
Positive Cores 0.28 0.55
1 44 (39%) 51 (46%) 1.00 (reference)
2 69 (61%) 59 (54%) 1.20 (0.66–2.18)
PIRADS <0.00011 2.72 (1.93–3.84)2 <0.0001
1 0 (0%) 2 (2%)
2 1 (1%) 13 (12%)
3 17 (15%) 41 (38%)
4 40 (35%) 31 (29%)
5 55 (49%) 20 (19%)
Cancer at MRI <0.0001 -3 -
Not visible 1 (1%) 18 (16%)
Visible 112 (99%) 92 (84%)
1Mantel-Haenszel p-value for trend = <0.0001
*T test or non parametric two-sample Wilcoxon test for continuous variables, as appropriate; Chi-Square test or Fisher’s Exact Test for categorical
variables, as appropriate
2One-unit increase OR
3Not entered in the multivariate model because it is a linear combination of other variables.
Note: significant ORs and p-values are in bold.
doi:10.1371/journal.pone.0139696.t003
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patients who are true positive and the proportion who are false positive, the latter weighted by
the relative harm of a false–positive and a false–negative result [18].
Statistical significance was defined as p<0.05. Statistical analysis was performed using SAS
software, version 9.2. The DCA was performed by using an Excel macro (Microsoft Office
Excel 2007).
Results
Table 1 presents the main characteristics of the study population. Sensitivity for MRI in identi-
fying tumors with the most unfavorable prognostic characteristics was extremely high, ranging
from 94% for large tumor volume to 100% for cancers with ECE, unfavorable prognosis and
SVI (Table 2). MRI presented an excellent ability in ruling out almost all the outcomes of inter-
est: NPV was 94% for upgrading and 100% for ECE, unfavorable prognosis and SVI (Table 2).
On the other side, specificity and PPV values were generally low for almost all the outcomes of
interest, with the exception of tumor volume, for which we found a PPV = 97%, probably due,
however, to the very low number of patients with tumor volume<0.5 ml (Table 2).
At univariate analysis (Tables 3–7) we found a significant association between PIRADS
score and GS upgrading, ECE, unfavorable prognosis and large tumor volume: the probability
of each outcome of interest increased with increasing PIRADS score (p<0.0001).The same
Table 4. Association of patient and tumor characteristics with extra capsular extension: univariate andmultivariate analysis.
Extra capsular extension Pvalue* Multivariate Odds Ratio (95%CI) Pvalue
“Yes” N (%) “No” N (%)
Volume^ 47.77 (±10.10) 47.99 (±15.66) 0.54 0.99 (0.96–1.03)2 0.73
Age^ 63.85 (±8.17) 62.41 (±8.31) 0.17 0.99 (0.95–1.04)2 0.79
Clinical Stage 0.02 0.02
cT1c 39 (75%) 152 (89%) 1.00 (reference)
cT2a 13 (25%) 19 (11%) 3.19 (1.22–8.35)
PSA^ 6.56 (±2.23) 5.86 (±1.78) 0.07 1.27 (1.03–1.57)2 0.03
PSA Density^ 0.14 (±0.04) 0.13 (±0.04) 0.10 -3 -
Positive Cores 0.34 0.68
1 19 (37%) 76 (44%) 1.00 (reference)
2 33 (63%) 95 (56%) 1.17 (0.55–2.49)
PIRADS <0.00011 5.27 (2.94–9.44)2 <0.0001
1 0 (0%) 2 (1%)
2 0 (0%) 14 (8%)
3 1 (2%) 57 (34%)
4 15 (29%) 56 (34%)
5 36 (69%) 39 (23%)
Cancer at MRI 0.01 -3 -
Not visible 0 (0%) 19 (11%)
Visible 52 (100%) 152 (89%)
1Mantel-Haenszel p-value for trend = <0.0001
*T test or non parametric two-sample Wilcoxon test for continuous variables, as appropriate; Chi-Square test or Fisher’s Exact Test for categorical
variables, as appropriate
2One-unit increase OR
3Not entered in the multivariate model because it is a linear combination of other variables.
Note: significant ORs and p-values are in bold.
doi:10.1371/journal.pone.0139696.t004
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trend was confirmed when restricting the analysis to patients with unfavorable prognosis and
primary GS = 4 (p = 0.01). No significant association was found between PIRADS score and
SVI (p = 0.28), although a significant trend for one–unit increase in PIRADS score was
observed even for this outcome (p = 0.03). Other possible predictors of unfavorable prognostic
characteristics were: age (upgrading, unfavorable prognosis), clinical stage (ECE, unfavorable
prognosis, SVI), PSA and PSA density (unfavorable prognosis).
At multivariate analysis (Table 3) the association of PIRADS score with upgrading, ECE,
unfavorable prognosis and large tumor volume was confirmed. The risk of having unfavorable
prognosis was more than quintupled for every unit increase of PIRADS score. Clinical stage
cT2a was a significant independent predictor of ECE, unfavorable prognosis and SVI, while
PSA was a significant independent predictor of ECE and unfavorable prognosis.
Fig 1 shows the ROC curves comparing models with and without PIRADS score. The differ-
ences between the correspondent AUC were statistically significant for upgrading (p<0.0001),
ECE (p<0.0001), unfavorable prognosis (p = 0.0002), and tumor volume (p = 0.01), whereas it
was not significant for SVI (p = 0.41) probably due to the very low number of patients with
SVI.
Fig 2 presents the decision curves for the multivariable models presented in Table 2 and Fig
1. Models including PIRADS score resulted in greater net benefit for almost all the outcomes of
interest if compared with models without the inclusion of PIRADS score, again with the only
exception of SVI. Inclusion of PIRADS score in prediction tools may therefore increase the net
Table 5. Association of patient and tumor characteristics with unfavorable prognosis: univariate andmultivariate analysis.
Unfavorable prognosis N (%) Favorable prognosis N (%) Pvalue* Multivariate Odds Ratio (95%CI) Pvalue
Volume^ 49.08 (±10.01) 47.70 (±15.33) 0.20 1.01 (0.97–1.05)2 0.74
Age^ 65.36 (±7.80) 62.19 (±8.29) 0.01 1.04 (0.98–1.10)2 0.26
Clinical Stage 0.03 0.04
cT1c 29 (74%) 162 (88%) 1.00 (reference)
cT2a 10 (26%) 22 (12%) 2.96 (1.06–8.22)
PSA^ 6.87 (±2.08) 5.84 (±1.83) 0.002 1.36 (1.08–1.72)2 0.01
PSA Density^ 0.14 (±0.04) 0.13 (±0.04) 0.04 -3 -
Positive Cores 0.38 0.98
1 14 (36%) 81 (44%) 1.00 (reference)
2 25 (67%) 103 (56%) 1.01 (0.43–2.37)
PIRADS <0.00011 5.42 (2.74–10.70)2 <0.0001
1 0 (0%) 2 (1%)
2 0 (0%) 14 (8%)
3 0 (0%) 58 (32%)
4 11 (28%) 60 (33%)
5 28 (72%) 47 (26%)
Cancer at MRI 0.05 -3 -
Not visible 0 (0%) 19 (10%)
Visible 39 (100%) 165 (90%)
1Mantel-Haenszel p-value for trend = <0.0001
*T test or non parametric two-sample Wilcoxon test for continuous variables, as appropriate; Chi-Square test or Fisher’s Exact Test for categorical
variables, as appropriate
2One-unit increase OR
3Not entered in the multivariate model because it is a linear combination of other variables.
Note: significant ORs and p-values are in bold.
doi:10.1371/journal.pone.0139696.t005
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benefit over almost all the range of probabilities when the outcome of interest is upgrading,
upstaging or their combination (unfavorable prognosis), while it results in increased net benefit
only at a threshold probability>80% when the outcome of interest is tumor volume.
Discussion
The proportion of men with low-risk PCa ranged from 16% in 2000 to 21% in 2006, showing
an increasing of 'watchful waiting option' from 0% to 39% over the same period[19]. These
data confirm the favorable outcomes of watchful waiting reported in the PIVOT study[20].
Thus the goal of PCa care is to identify and treat only men with clinically significant disease. In
this setting, AS aims to avoid unnecessary treatment in men with slow-growing PCa, although
current risk stratification schemes misclassify some patients. Selvadurai et al observed that
about one-third of those men undergoing deferred RP had adverse features at the time of sur-
gery, such as extracapsular extension, high-grade disease, or positive margins[21]. Circulating
biomarkers represent a promising approach to identify men with apparently low-risk biopsy
pathology, but who harbor potentially aggressive tumors unsuitable for AS[22,23]. Recently
van den Bergh et al. provided a summary of the current studies examining imaging and novel
biomarkers in AS for PCa, emphasizing their burden role of monitoring during AS[4]. Several
studies have suggested the benefit of early repeat biopsy or more extended biopsy to reduce the
Table 6. Association of patient and tumor characteristics with tumor volume: univariate andmultivariate analysis.
Tumor volume Pvalue* Multivariate Odds Ratio (95%CI) Pvalue
0.5 ml N (%) <0.5 ml N (%)
Volume^ 47.52 (±11.25) 55.25 (±42.24) 0.30 0.99 (0.96–1.01)2 0.31
Age^ 62.66 (±8.39) 64.27 (±5.96) 0.53 0.97 (0.87–1.08)2 0.58
Clinical Stage 0.68 0.47
cT1c 181 (86%) 10 (83%) 1.00 (reference)
cT2a 30 (14%) 2 (17%) 0.49 (0.07–3.42)
PSA^ 6.05 (±1.92) 5.41 (±1.68) 0.26 1.33 (0.89–1.97)2 0.17
PSA Density^ 0.13 (±0.04) 0.12 (±0.05) 0.39 -3 -
Positive Cores 0.26 0.62
1 88 (42%) 7 (58%) 1.00 (reference)
2 123 (58%) 5 (42%) 1.41 (0.37–5.43)
PIRADS <0.00011 3.43 (1.56–7.65)2 0.002
1 2 (1%) 0 (0%)
2 10 (5%) 4 (40%)
3 53 (25%) 5 (50%)
4 71 (34%) 0 (0%)
5 74 (35%) 1 (10%)
Cancer at MRI <0.0001 -3 -
Not visible 13 (6%) 6 (50%)
Visible 198 (94%) 6 (50%)
1Mantel-Haenszel p-value for trend = 0.0002
*T test or non parametric two-sample Wilcoxon test for continuous variables, as appropriate; Chi-Square test or Fisher’s Exact Test for categorical
variables, as appropriate
2One-unit increase OR
3Not entered in the multivariate model because it is a linear combination of other variables.
Note: significant ORs and p-values are in bold.
doi:10.1371/journal.pone.0139696.t006
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risk of unfavorable disease on RP specimens regardless of how AS criteria are defined[24,25].
Kuru et al in a retrospective evaluation of the PIRADS in mpMRI based on single cores and
single-core histology, confirmed a significant correlation between this decision-support scoring
system and histopathology[26]. The adding performance of MRI to the initial clinical evalua-
tion of men with clinically low risk PCa helped prediction, showing that an overall PIRADS
score of 5 had a high sensitivity for GS upgrading on confirmatory biopsy, and suggesting a
potential role in patients’ selection for AS[27]..Recently, Abdi et al demonstrated on multivari-
ate analysis an increased rate of AS termination for patients with PIRADS score 4 or 5 (vs 3)
undergoing MRI fusion technology during transrectal ultrasound-guided biopsy[28]. Bitten-
court et al in 133 consecutive PCa patients, who underwent prostatectomy, showed moderate
overall accuracy of ESUR/PIRADS criteria in the prediction of EPE in a subpopulation with
intermediate to high-risk disease and large-volume tumors [29].
Other authors[30,31] showed that MRI does not improve the prediction of high-risk and/or
non organ-confined disease in a RP specimen.
According to previous reports [32,33], our study supports the prognostic accuracy of MRI
and PIRADS score in predicting pathological features such as GS upgrading, ECE, unfavorable
prognosis and large tumor volume in a cohort of patients eligible for AS. Particularly,
Table 7. Association of patient and tumor characteristics with seminal vesicle invasion: univariate andmultivariate analysis.
Seminal vesicle invasion Pvalue* Multivariate Odds Ratio (95%CI) Pvalue
“Yes” (%) “No” (%)
Volume^ 46.14 (±3.72) 47.94 (±14.76) 0.98 1.01 (0.92–1.10) 2 0.91
Age^ 66.57 (±5.70) 62.63 (±8.35) 0.17 1.06 (0.92–1.21) 2 0.44
Clinical Stage 0.01 0.02
cT1c 3 (43%) 187 (87%) 1.00 (reference)
cT2a 4 (57%) 28 (13%) 7.78 (1.44–41.93)
PSA^ 6.04 (±1.91) 6.01 (±1.91) 0.99 1.01 (0.63–1.61) 2 0.98
PSA Density^ 0.13 (±0.04) 0.13 (±0.04) 0.89 -3 -
Positive Cores 0.70 0.88
1 2 (29%) 92 (43%) 1.00 (reference)
2 5 (71%) 123 (57%) 1.15 (0.19–6.98)
PIRADS 0.281 3.97 (0.92–17.09) 2 0.06
1 0 (0%) 2 (1%)
2 0 (0%) 14 (7%)
3 0 (0%) 58 (27%)
4 2 (29%) 68 (32%)
5 5 (71%) 70 (33%)
Cancer at MRI 1.00 -3 -
Not visible 0 (0%) 19 (9%)
Visible 7 (100%) 196 (91%)
^mean (± SD)
*T test or non parametric two-sample Wilcoxon test for continuous variables, as appropriate; Chi-Square test or Fisher’s Exact Test for categorical
variables, as appropriate
1Mantel-Haenszel p-value for trend = 0.03
2 One-unit increase OR
3 Not entered in the multivariate model because it is a linear combination of other variables.
Note: significant ORs and p-values are in bold.
doi:10.1371/journal.pone.0139696.t007
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considering the multivariable model for predicting unfavorable prognosis, we found a strong
association with one unit increase PIRADS score as well as with one unit increase PSA and
Fig 1. ROCCurves comparing models with and without inclusion of PIRADS score for a) Gleason score (GS) upgrading, b) extra capsular
extension, c) unfavorable prognosis, d) tumor volume and e) seminal vesicle invasion.
doi:10.1371/journal.pone.0139696.g001
Fig 2. Decision curve analysis of the effect of predictionmodels on the detection of a) upgrading, b) extra capsular extension, c) unfavorable
prognosis, d) tumor volume and e) seminal vesicle invasion.Model with PIRADS score (red line) is plotted against treat none (violet line), treat all (green
line) and model without PIRADS score (blue line).
doi:10.1371/journal.pone.0139696.g002
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clinical stage cT2a compared with cT1c. DCA further confirmed the benefit given by using a
model including PIRADS score when compared with the decision of treating all patients or
treating none, as well as compared with a model that do not include this scoring system. The
inclusion of PIRADS score in prediction tools may increase the net benefit over almost all the
range of probabilities when the outcome of interest is GS upgrading, ECE or their combination.
In particular, we found that the PIRADS score for detecting cancer was highly sensitive for
both ECE and seminal vesicle invasion, although we did not use PIRADS-specific scores in
order to assess these variables. Also, it results in increased net benefit at a threshold
probability>80% when the outcome of interest was tumor volume.
Conclusions
Our findings show that mpMRI and PIRADS scoring are feasible tools in clinical setting and
could be used as decision-support systems for a more accurate selection of patients eligible for
AS. ROC curves and DCA showed the higher accuracy of the models including PIRADS score
in predicting GS upgrading, ECE, unfavorable prognosis and tumor volume at final histology.
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